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Dear Editor,
With interest we read the paper by
Kiers et al. [1] suggesting that cysta-
tin C (CyC) is not a useful parameter
for residual renal function during
continuous venovenous hemoﬁltra-
tion (CVVH). We previously found
that the sieving coefﬁcient (SC) for
the cellulose triacetate membrane for
CyC is approximately 0.50 [2]. On
the basis of the constant CyC pro-
duction reported in the literature, we
hypothesized that predilution CVVH
(2 l/h) is unlikely to inﬂuence serum
CyC levels, although we did not
determine changes in serum CyC [2].
Using the same dose (2 l/h, predilu-
tion) but a different membrane
(polyacrylonitrile), Kiers et al. report
a signiﬁcant decrease of CyC after
24 h of CVVH in six patients with
acute kidney injury (AKI). The
authors do not report whether the
patients were anuric during CVVH.
Several factors may explain the
opposite results. First, the cellulose
triacetate membrane and the polyac-
rylonitrile membrane may behave
differently in their ability to remove
CyC [3]. Unfortunately, Kiers et al.
did not measure CyC in the ultraﬁl-
trate, and thus we are not informed on
the SC. Second, it is possible that the
patients in the study by Kiers et al.
had recovering renal function during
CVVH, although this is not very
likely. Finally, the assumption that
the generation rate of CyC in criti-
cally ill and non-critically ill patients
is comparable may be wrong. To date,
only few circumstances have been
identiﬁed that have an impact on the
production of CyC; nevertheless, this
was never studied in critically ill
patients [4]. We performed a small
pilot study in six consecutive patients
in order to determine the removal of
CyC during CVVH and its effect on
serum CyC levels. Patients were
included if ﬁlter-down time was no
longer than 2 h. We applied postdi-
lution CVVH (35 ml/kg/h) and used
either a polysulfone membrane (AV
600; Fresenius, Oberursel, Germany)
or a cellulose triacetate membrane
(UF 205; Nipro Europe, Zaventem,
Belgium). Serum CyC decreased after
the initiation of CVVH both in oligo-
anuric and non-oliguric patients
(Fig. 1). In the non-oliguric patients
CyC levels increased after cessation
of CVVH, suggesting that CVVH
played an important role in the
removal of CyC. When corrected for
possible incomplete mixing by using
the SC of urea, which should be 1 by
deﬁnition, we found an SC of
0.49 ± 0.04 for the cellulose triace-
tate membrane and 0.45 ± 12 for the
polysulfone membrane (p = 1.00).
The CVVH dose in the present study
was higher than in our earlier study
and this may account for the decrease
of CyC. Another possibility is that
contrary to what we proposed earlier,
CyC production is reduced in criti-
cally ill patients. The present pilot
study and the study by Kiers et al. are
limited by the small number of
patients. Both studies, however, reach
the same conclusion suggesting that
during CVVH serum CyC is of little
Fig. 1 TimecourseofserumcystatinCandserumcreatinineduringcontinuousvenovenous
hemoﬁltration (CVVH). Curves represent individual patients. Open circles, cellulose
triacetate membrane, closed circles polysulfone membrane. Left panel oligo-anuric patients.
AllpatientsreceivedCVVHfromday0untilday8.Rightpanelnon-oliguricpatients.CVVH
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CyC and decreases its serum levels.
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